IOL Chemicals and Pharmaceuticals Limited (BOM:524164)
India
· Delayed Price · Currency is INR 74.06
+3.14 (4.43%)
At close: Mar 6, 2026
BOM:524164 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 22,274 | 20,792 | 21,328 | 22,171 | 21,840 | 19,670 | Upgrade
|
| Revenue Growth (YoY) | 8.37% | -2.51% | -3.80% | 1.52% | 11.03% | 3.83% | Upgrade
|
| Cost of Revenue | 14,701 | 14,013 | 14,041 | 15,605 | 15,812 | 11,096 | Upgrade
|
| Gross Profit | 7,573 | 6,779 | 7,287 | 6,566 | 6,028 | 8,573 | Upgrade
|
| Selling, General & Admin | 2,321 | 2,183 | 2,027 | 1,686 | 1,415 | 1,157 | Upgrade
|
| Other Operating Expenses | 2,860 | 2,573 | 2,954 | 2,617 | 2,019 | 1,497 | Upgrade
|
| Operating Expenses | 5,966 | 5,477 | 5,610 | 4,765 | 3,867 | 3,043 | Upgrade
|
| Operating Income | 1,607 | 1,303 | 1,677 | 1,801 | 2,161 | 5,531 | Upgrade
|
| Interest Expense | -105.1 | -99 | -108.4 | -106.9 | -24.3 | -9.4 | Upgrade
|
| Interest & Investment Income | 110.4 | 110.4 | 143.2 | 167.3 | 182 | 159.9 | Upgrade
|
| Currency Exchange Gain (Loss) | 83.4 | 83.4 | 130.8 | 70.6 | 104.4 | 69.1 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.9 | -18.5 | -28.6 | -42.2 | -25.1 | -39.9 | Upgrade
|
| EBT Excluding Unusual Items | 1,694 | 1,379 | 1,814 | 1,890 | 2,398 | 5,710 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.2 | 0.2 | 0.2 | 2.3 | 0.2 | 0.1 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1 | 1 | 1.4 | -3.3 | -2.4 | 0.5 | Upgrade
|
| Asset Writedown | -0.8 | -0.8 | -0.4 | -2.6 | -8.5 | -1.5 | Upgrade
|
| Other Unusual Items | -112.1 | - | 1.1 | 0.3 | -139 | 4.4 | Upgrade
|
| Pretax Income | 1,583 | 1,380 | 1,817 | 1,887 | 2,249 | 5,714 | Upgrade
|
| Income Tax Expense | 423.5 | 368.9 | 472.2 | 495.1 | 571.8 | 1,268 | Upgrade
|
| Net Income | 1,159 | 1,011 | 1,344 | 1,391 | 1,677 | 4,446 | Upgrade
|
| Net Income to Common | 1,159 | 1,011 | 1,344 | 1,391 | 1,677 | 4,446 | Upgrade
|
| Net Income Growth | 19.15% | -24.82% | -3.38% | -17.02% | -62.28% | 23.05% | Upgrade
|
| Shares Outstanding (Basic) | 293 | 294 | 294 | 294 | 294 | 292 | Upgrade
|
| Shares Outstanding (Diluted) | 293 | 294 | 294 | 294 | 294 | 292 | Upgrade
|
| Shares Change (YoY) | -0.09% | - | - | - | 0.64% | 2.32% | Upgrade
|
| EPS (Basic) | 3.95 | 3.44 | 4.58 | 4.74 | 5.71 | 15.24 | Upgrade
|
| EPS (Diluted) | 3.95 | 3.44 | 4.58 | 4.74 | 5.71 | 15.24 | Upgrade
|
| EPS Growth | 19.16% | -24.89% | -3.38% | -17.02% | -62.52% | 20.24% | Upgrade
|
| Free Cash Flow | - | -349.3 | 156.1 | -895.5 | -602.4 | 2,716 | Upgrade
|
| Free Cash Flow Per Share | - | -1.19 | 0.53 | -3.05 | -2.05 | 9.31 | Upgrade
|
| Dividend Per Share | 1.000 | 0.800 | 1.000 | 0.800 | 0.800 | 1.200 | Upgrade
|
| Dividend Growth | 25.00% | -20.00% | 25.00% | - | -33.33% | 100.00% | Upgrade
|
| Gross Margin | 34.00% | 32.61% | 34.17% | 29.61% | 27.60% | 43.59% | Upgrade
|
| Operating Margin | 7.22% | 6.27% | 7.86% | 8.12% | 9.90% | 28.12% | Upgrade
|
| Profit Margin | 5.20% | 4.86% | 6.30% | 6.28% | 7.68% | 22.60% | Upgrade
|
| Free Cash Flow Margin | - | -1.68% | 0.73% | -4.04% | -2.76% | 13.81% | Upgrade
|
| EBITDA | 2,378 | 2,008 | 2,295 | 2,253 | 2,584 | 5,910 | Upgrade
|
| EBITDA Margin | 10.68% | 9.66% | 10.76% | 10.16% | 11.83% | 30.05% | Upgrade
|
| D&A For EBITDA | 770.58 | 705.1 | 617.8 | 452.2 | 422.8 | 379.4 | Upgrade
|
| EBIT | 1,607 | 1,303 | 1,677 | 1,801 | 2,161 | 5,531 | Upgrade
|
| EBIT Margin | 7.22% | 6.27% | 7.86% | 8.12% | 9.90% | 28.12% | Upgrade
|
| Effective Tax Rate | 26.76% | 26.74% | 26.00% | 26.24% | 25.43% | 22.20% | Upgrade
|
| Revenue as Reported | 22,515 | 21,016 | 21,629 | 22,427 | 22,161 | 19,913 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.